cemsidomide — Interim data
H2 2026
C4T expects to provide an update on the dose escalation progress in the second half of 2026 with data from all cohorts expected in mid-2027.Source filing
CCCC biotech catalysts & pipeline
C4 THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
cemsidomide — Full data
Mid-2027
Mid-2027: Data from all cohorts evaluatedSource filing
cemsidomide — Full data
mid-2027
C4T expects to provide an update on the dose escalation progress in the second half of 2026 with data from all cohorts expected in mid-2027.Source filing
cemsidomide — Initial data
H2 2027
Enrollment for the Phase 2 MOMENTUM trial is expected to be complete in the first quarter of 2027 with initial investigator-assessed overall response rate data expected in the second half of 2027.Source filing
cemsidomide — NDA/BLA submission
Late 2028
• By year-end 2028, submit new drug application evaluating cemsidomide and dexamethasone for potential accelerated approval in fourth line or later.Source filing